Robert H. Brookline Rubin

Robert H. Brookline Rubin's AcademicInfluence.com Rankings

Philosophy

#4524

World Rank

#7074

Historical Rank

Logic

#1957

World Rank

#2837

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert H. Brookline Rubin's Degrees

Doctorate Medicine Harvard University

Why Is Robert H. Brookline Rubin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert H. Brookline Rubin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (2002) (3019)
Infection in organ-transplant recipients. (1998) (953)
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. (2007) (544)
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. (1981) (485)
Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (435)
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. (1981) (431)
Impact of cytomegalovirus infection on organ transplant recipients. (1990) (426)
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. (1997) (422)
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. (2003) (406)
Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. (1990) (355)
Infectious disease complications of renal transplantation. (1993) (350)
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. (1981) (347)
Infection in the renal transplant recipient. (1981) (337)
NEUROLOGIC COMPLICATIONS OF BACTERIAL ENDOCARDITIS (1978) (305)
The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. (1997) (299)
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. (1979) (269)
Infections and anti–tumor necrosis factor α therapy (2003) (269)
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. (1975) (268)
Clinical Approach to Infection in the Compromised Host (2002) (250)
Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients (1995) (247)
Infection in the Organ Transplant Recipient (1994) (240)
Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. (1995) (229)
SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2 (1992) (225)
Infections and anti-tumor necrosis factor alpha therapy. (2003) (222)
The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. (1989) (221)
111In-labeled nonspecific immunoglobulin scanning in the detection of focal infection. (1989) (205)
Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. (1978) (201)
Cytomegalovirus prophylaxis in solid organ transplant recipients. (1996) (188)
Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. (1981) (187)
Hepatic abscess: changes in clinical, bacteriologic and therapeutic aspects. (1974) (186)
BK virus in solid organ transplant recipients: an emerging syndrome. (2001) (179)
INFECTIOUS DISEASE SYNDROMES ATTRIBUTABLE TO CYTOMEGALOVIRUS AND THEIR SIGNIFICANCE AMONG RENAL TRANSPLANT RECIPIENTS (1977) (179)
Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. (1983) (173)
Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli (1989) (171)
MULTICENTER SEROEPIDEMIOLOGIC STUDY OF THE IMPACT OF CYTOMEGALOVIRUS INFECTION ON RENAL TRANSPLANTATION (1985) (164)
Preemptive therapy in immunocompromised hosts. (1991) (162)
Central Nervous System Infection in the Chronically Immunosuppressed (1982) (159)
Glomerulopathy Associated with Cytomegalovirus Viremia in Renal Allografts (1981) (157)
Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. (2001) (156)
Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. (1986) (149)
A serological investigation of BK virus and JC virus infections in recipients of renal allografts. (1988) (147)
Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. (1983) (141)
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. (1981) (140)
Clinical aspects of fungal infection in organ transplant recipients. (1994) (131)
Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. (1995) (130)
Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis (2000) (125)
The Renal Transplant Patient with Fever and Pulmonary Infiltrates: Etiology, Clinical Manifestations, and Management (1980) (120)
Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. (1980) (120)
Dermatologic Manifestations of Infections in Immunocompromised Patients (1985) (117)
Cytomegalovirus infection in dialysis patients and personnel. (1978) (114)
Varicella in pediatric renal transplant recipients. (1992) (113)
A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. (1982) (108)
EVOLVING USE OF OKT3 MONOCLONAL ANTIBODY FOR TREATMENT OF RENAL ALLOGRAFT REJECTION (1984) (107)
Specific and nonspecific imaging of localized Fisher immunotype 1 Pseudomonas aeruginosa infection with radiolabeled monoclonal antibody. (1988) (105)
Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients (2004) (105)
The release of four mediators of immediate hypersensitivity from human leukemic basophils. (1975) (104)
Impact of hepatitis on renal transplantation. (1981) (101)
Single-Dose Amoxicillin Therapy for Urinary Tract Infection: Multicenter Trial Using Antibody-Coated Bacteria Localization Technique (1980) (101)
Detection of acute inflammation with 111In-labeled nonspecific polyclonal IgG. (1988) (100)
Salmonellosis: Microbiologic, pathologic, and clinical features (1977) (97)
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. (2005) (96)
Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. (1993) (96)
Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. (1997) (96)
Radiolabeled, nonspecific, polyclonal human immunoglobulin in the detection of focal inflammation by scintigraphy: comparison with gallium-67 citrate and technetium-99m-labeled albumin. (1989) (91)
Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs. (1991) (91)
The spectrum of Salmonella infection. (1988) (89)
Autoradiographic method for quantitation of radiolabeled proteins in tissues using indium-111. (1989) (87)
Surgical wound infection: epidemiology, pathogenesis, diagnosis and management (2006) (87)
Antimicrobial strategies in the care of organ transplant recipients (1993) (87)
The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the ‘silo hypothesis’ (2007) (86)
Localization of Fc and Fab fragments of nonspecific polyclonal IgG at focal sites of inflammation. (1990) (85)
Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography (1993) (83)
Pharmacokinetic Imaging (2002) (82)
Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS (1993) (80)
USE OF ANTITHYMOCYTE GLOBULIN FOR REVERSAL OF ACUTE ALLOGRAFT REJECTION (1979) (80)
Clinical Approach to Infection in the Compromised Host (2002) (78)
The acquired immunodeficiency syndrome and transplantation. (1987) (78)
Infection of the central nervous system in organ transplant recipients. (1988) (77)
A murine model of myocardial microvascular thrombosis. (1999) (76)
Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. (1999) (76)
IGA NEPHROPATHY IN HLA‐IDENTICAL SIBLINGS (1978) (76)
Hepatitis C virus and organ transplantation. (1996) (75)
From the National Institutes of Health. Summary of a workshop on cytomegalovirus infections during organ transplantation. (1979) (75)
Infection in the Renal and Liver Transplant Patient (1988) (73)
Uremia and host defenses. (1990) (72)
Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation. (1984) (71)
Prevention and treatment of cytomegalovirus disease in heart transplant patients. (2000) (71)
Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole1 (2003) (71)
Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy (2003) (69)
Mononuclear cells in acute allograft glomerulopathy. (1987) (69)
In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. (1993) (65)
The effect of infection on T lymphocyte subpopulations: a preliminary report. (1981) (64)
Short-Course Ciproflox Treatment of Acute Uncomplicated Urinary Tract Infection in Women: The Minimum Effective Dose (1995) (64)
Cytokines as potential vaccine adjuvants (1994) (64)
Approach to immunization in the immunosuppressed host. (1990) (63)
Technetium-99m-labeled chemotactic peptides: comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. (1993) (63)
Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. (1996) (63)
Adverse reactions to duck embryo rabies vaccine. Range and incidence. (1973) (61)
The hepatotoxicity of antifungal medications in bone marrow transplant recipients. (2005) (61)
Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. (1981) (61)
Production of a low molecular weight eosinophil polymorphonuclear leukocyte chemotactic factor by anaplastic squamous cell carcinomas of human lung. (1978) (61)
Amoxicillin and Potassium Clavulanate: An Antibiotic Combination Mechanism of Action, Pharmacokinetics, Antimicrobial Spectrum, Clinical Efficacy and Adverse Effects (1984) (60)
Radionuclide imaging of experimental atherosclerosis with nonspecific polyclonal immunoglobulin G. (1989) (57)
Evolving trends in liver transplantation: an outcome and charge analysis. (1998) (57)
IMMUNOGENICITY OF HEPATITIS B VACCINE IN RENAL TRANSPLANT RECIPIENTS (1985) (57)
The prevention of infection post‐transplant: the role of prophylaxis, preemptive and empiric therapy (2006) (56)
The acquired immunodeficiency syndrome (AIDS) and infection with the human immunodeficiency virus (HIV) (1988) (56)
Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. (1989) (56)
Viral infection in the renal transplant recipient (1992) (55)
The role of positron emission tomography in pharmacokinetic analysis. (1997) (55)
Invasive aspergillus infection: possible non-ward common source within the hospital environment. (1989) (54)
Cytomegalovirus in solid organ transplantation (2001) (54)
The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies (1999) (53)
Single-dose therapy with trimethoprim-sulfamethoxazole for urinary tract infection in women. (1982) (53)
Infection imaging with technetium-99m-labeled chemotactic peptide analogs. (1994) (52)
A case of human rabies in Kansas: epidemiologic, clinical, and laboratory considerations. (1970) (51)
Pharmacokinetics of [18F]Trovafloxacin in Healthy Human Subjects Studied with Positron Emission Tomography (1998) (50)
Noninvasive renal diagnostic studies. (1988) (50)
The use of radiolabeled nonspecific immunoglobulin in the detection of focal inflammation. (1994) (49)
Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant‐induced gastrointestinal toxicities (2001) (49)
Infection in the Renal Transplant Patient (1982) (48)
Opportunistic fungal and bacterial infection in the renal transplant recipient. (1992) (47)
The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. (2002) (45)
Mapping of local renal blood flow with PET and H(2)(15)O. (2002) (45)
The compromised host as sentinel chicken. (1987) (44)
Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. (1998) (43)
An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic injury. (1996) (42)
An approach to evaluating antibacterial agents in the treatment of urinary tract infection. (1992) (42)
The problem of human immunodeficiency virus (HIV) infection and transplantation (1988) (42)
Indium-111-labeled human nonspecific immunoglobulin G: a new radiopharmaceutical for imaging infectious and inflammatory foci. (1992) (41)
Interferon and BK Papovavirus--clinical and laboratory studies. (1980) (41)
The impact of infection on the outcome of transplantation. (1991) (41)
Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. (1992) (40)
Prevention dof recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir (2000) (39)
Structure and copy number of gene clusters related to the pap P-adhesin operon of uropathogenic Escherichia coli (1989) (39)
Defective human mononuclear leukocyte chemotaxis as an index of host resistance to malignant melanoma. (1976) (39)
Infection in the organ transplant recipient. An overview. (1995) (38)
Central nervous system infection in the compromised host. (1985) (38)
Neurologic complications following the treatment of human Babesia microti infection with diminazene aceturate. (1979) (38)
Postexposure rabies prophylaxis with human rabies immune globulin. (1974) (38)
Utility of the indium 111-labeled human immunoglobulin G scan for the detection of focal vascular graft infection. (1989) (37)
Dietary marine lipid does not alter susceptibility of (NZBxNZW)F1 mice to pathogenic microorganisms. (1989) (36)
Bacteremic hemophilus influenzae type B cellulitis in the adult. (1977) (36)
Dermatologic manifestations of infection in the compromised host. (1983) (36)
Introduction to the Immunocompromised Host Society consensus conference on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients. (2001) (36)
New developments in cytomegalovirus prevention and management. (1993) (35)
Isolation of adenovirus type 34 from a renal transplant recipient with interstitial pneumonia. (1977) (35)
Myopericarditis and enhanced dystrophic cardiac calcification in murine cytomegalovirus infection. (1986) (34)
Noninvasive, real-time monitoring of renal function during critical care. (1994) (34)
Infection: the new problems. (1989) (34)
Single-dose amoxicillin therapy of uncomplicated pediatric urinary tract infections. (1983) (33)
Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice (1989) (33)
USEFULNESS OF THE ANTIBODY‐COATED BACTERIA ASSAY IN THE MANAGEMENT OF URINARY TRACT INFECTION IN THE RENAL TRANSPLANT PATIENT (1979) (33)
Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. (2006) (33)
Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. (1983) (33)
Single-Dose Amoxicillin Therapy for Urinary Tract Infection-Reply (1981) (33)
New approaches to the treatment of urinary tract infection. (1987) (33)
Effect of carbohydrate modification on the localization of human polyclonal IgG at focal sites of bacterial infection. (1992) (32)
Accumulation of immunoglobulin G at focal sites of inflammation (2004) (32)
Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. (1999) (32)
Primary cytomegalovirus infection following cardiac transplantation in a murine model. (1984) (31)
Cure of hemophilia A by orthotopic liver transplantation. (1988) (30)
Importance of CMV in the transplant population. (1999) (30)
Renal transplantation and related infections. (1993) (30)
Adenosine deaminase binding protein, a new diagnostic marker for kidney disease. (1985) (30)
Viral infection in the renal transplant patient. (1983) (29)
The impact of cyclosporine therapy on the occurrence of infection in the renal transplant recipient. (1986) (29)
Disseminated Mycobacterium avium‐intracellulare in a kidney transplant recipient (2001) (29)
Safety and efficacy of granulocyte colony‐stimulating factor in kidney and liver transplant recipients (2000) (27)
Lack of effect of hepatitis B vaccine on T-cell phenotypes. (1984) (26)
Single-dose amoxicillin therapy of acute uncomplicated urinary tract infections in women (1984) (26)
Effects of long-term lithium administration on renal structure and function in rats. A distinctive tubular lesion. (1984) (26)
Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography (1996) (26)
9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice (1987) (26)
Immunoglobulin response to rabies vaccine in man. (1971) (26)
Antithymocyte globulin as the primary treatment for renal allograft rejection. (1983) (25)
Editorial Response: Cytomegalovirus Disease and Allograft Loss After Organ Transplantation (1998) (25)
Solid organ transplantation in HIV-infected individuals: obstacles and opportunities. (2001) (25)
Etiology and Management of the Compromised Patient with Fever and Pulmonary Infiltrates (1988) (25)
18F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219). (1996) (25)
Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. (1999) (24)
Immunization strategies for the immunocompromised host: the need for immunoadjuvants. (1989) (24)
Overview: pathogenesis of fungal infections in the organ transplant recipient. (2002) (24)
Fungal and bacterial infections in the immunocompromised host (2006) (23)
Escherichia coli-specific T lymphocytes in experimental pyelonephritis. (1988) (23)
Systemic salmonellosis in patients with disseminated histoplasmosis. Case for 'macrophage blockade' caused by Histoplasma capsulatum. (1987) (22)
Opportunistic infections in renal allograft recipients. (1988) (22)
Recent advances in the diagnosis and management of infection in the organ transplant recipient. (2000) (22)
Combined kidney and pancreas transplantation in diabetics. (1988) (21)
Empiric antibacterial therapy in granulocytopenia induced by cancer chemotherapy. (1988) (21)
Localization of indium-111-immunoglobulin G, technetium-99m-immunoglobulin G and indium-111-labeled white blood cells at sites of acute bacterial infection in rabbits. (1993) (21)
Understanding and diagnosing infectious complications in the immunocompromised host. Current issues and trends. (1993) (21)
A consideration of potential donors with active infection – is this a way to expand the donor pool? (1998) (20)
Cell-mediated immunity in experimental cytomegalovirus infections: a perspective. (1990) (20)
Rabies in citizens of the United States, 1963-1968: epidemiology, treatment, and complications of treatment. (1969) (20)
Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase binding protein. (1987) (20)
Imaging of Pneumocystis carinii pneumonia with 111In‐labelled non‐specific polyclonal IgG: an experimental study in rats (1991) (20)
BK papovavirus infections in renal transplant recipients: contribution of donor kidneys. (1982) (19)
Activation of latent murine cytomegalovirus in cardiac explant and cell cultures. (1985) (19)
Case record of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2003. A 43-year-old man with fever, rapid loss of vision in the left eye, and cardiac findings. (2003) (19)
Viral infections in organ transplantation. (1998) (18)
Liver disease in the organ transplant recipient: Etiology, clinical impact, and clinical management (1991) (18)
EVOLVING TRENDS IN LIVER TRANSPLANTATION (1999) (18)
Immunologic monitoring with monoclonal antibodies to human T-cell subsets. (1981) (18)
Opportunistic infections in the cardiac transplant patient. (1996) (18)
The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: the case for passive-active immunization. (1986) (18)
The bidirectional relationship between cytomegalovirus and allograft injury. (2001) (17)
T-lymphocyte subset phenotypes: a multisite evaluation of normal subjects and patients with AIDS. (1985) (17)
Smallpox vaccination and the patient with an organ transplant. (2003) (17)
Cytomegalovirus disease and allograft loss after organ transplantation. (1998) (17)
Localization and antibiotic management of urinary tract infection. (1979) (16)
Cytomegalovirus excretion 2-14 years after renal transplantation. (1979) (16)
Prevention of cytomegalovirus infection in organ transplant recipients (2000) (16)
Mycobacterial and Nocardial Diseases in the Compromised Host (2002) (16)
The infectious disease problems of the diabetic renal transplant recipient. (1995) (16)
Cytomegalovirus infection in the liver transplant recipient. Epidemiology, pathogenesis, and clinical management. (1997) (15)
Synthesis of a 11C-labeled NK1 receptor ligand for PET studies. (1995) (15)
Biodistribution and dosimetry of technetium-99m-hydrazino nicotinamide IgG: comparison with indium-111-DTPA-IgG. (1996) (15)
Urinary tract infection: significance and management. (1986) (15)
Management of Tuberculosis in the Transplant Recipient (2005) (15)
Detection of acute bacterial infection within soft tissue injuries using a 99mTc-labeled chemotactic peptide. (1995) (14)
POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER AND OKT3. REPLY (1991) (14)
Clinical Approach to the Compromised Host with Fever and Pulmonary Infiltrates (2002) (14)
Radionuclide imaging of infection in the immunocompromised host. (1996) (14)
Fluconazole in the Treatment of Invasive Candidal and Cryptococcal Infections in Organ Transplant Recipients (1990) (14)
Synthesis and biodistribution of 18F-labeled fleroxacin. (1993) (14)
Diagnostic efficacy and safety of computed tomography-guided transthoracic needle biopsy in patients with hematologic malignancies. (2009) (14)
Preparation and pharmacokinetics of 11C labeled stavudine (d4T). (2004) (13)
Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy (2006) (13)
The interaction of immunosuppression with infection in the organ transplant recipient. (1994) (13)
Risks versus benefits of contrast medium exposure in renal allograft recipients. (1983) (13)
Clinical approach to viral and fungal infections in the renal transplant patient. (1992) (13)
Effect of isoelectric point on biodistribution and inflammation imaging with indium-111-labelled IgG (2004) (13)
In Vivo Imaging in Drug Discovery and Design (1994) (13)
Human rabies immune globulin. Clinical trials and effects on serum anti- -globulins. (1973) (12)
Transplant infectious disease: a moving target (2008) (12)
Ciprofloxacin in management of urinary tract infection. (1988) (12)
Changes in the phenotype of T-cell subset determinants following murine cytomegalovirus infection. (1986) (12)
The selective use of antilymphocyte serum for cyclosporine treated patients with renal allograft dysfunction. (1987) (12)
Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency (1985) (11)
Real-time monitoring of renal function during ischemic injury in the rhesus monkey. (1995) (11)
Effect of interferon alpha on natural killer cell cytotoxicity in kidney transplant recipients. (1984) (11)
T lymphocyte responses to antigens of gram-negative bacteria in pyelonephritis. (1993) (10)
FUNGAL INFECTION IN THE ORGAN TRANSPLANT RECIPIENT (1998) (10)
Postmenopausal tubo-ovarian abscess due to Pseudomonas aeruginosa in a renal transplant patient: a case report and review of the literature. (2001) (10)
Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. (1997) (10)
Sucdessful hemodialysis of patients at high risk of hemorrhage using the exVal dialyzer (1986) (10)
Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. (1981) (9)
In vivo tissue distribution of CD4 lymphocytes in mice determined by radioimmunoscintigraphy with an 111In-labeled anti-CD4 monoclonal antibody. (1996) (9)
Clinical Management of Urinary Tract Infection (1982) (9)
Post transfusion viral infections. (1988) (9)
Regional perfusion, oxygen metabolism, blood volume and immunoglobulin G accumulation at focal sites of infection in rabbits (2004) (8)
Comparison of 99Tcm-labelled monoclonal anti‐granulocyte antibody and 111 In‐labelled IgG for the detection of focal sites of infection in rats (1991) (8)
Studies of immediate hypersensitivity in a patient with Acanthocheilonema perstans filarial infection. (1975) (8)
Prevention of infection in the liver transplant recipient. (1996) (8)
Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. (1997) (8)
Thein vivo andin vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection (1989) (8)
The therapeutic prescription for the transplant patient (2002) (7)
Protective effects of E5, an antiendotoxin monoclonal antibody, in the ovine pulmonary circulation. (1993) (7)
Overview of pneumonia in the compromised host. (1986) (7)
Imaging of focal sites of inflammation in rhesus monkeys with 99mTc-labeled human polyclonal IgG. (1994) (6)
1506 SINGLE DOSE AMOXICILLIN (S) TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS (UTI) AS EFFECTIVE AS CONVENTIONAL THERAPY (C) (1981) (6)
Positron emission tomographic analysis of central dopamine D1 receptor binding in normal subjects treated with the atypical neuroleptic, SDZ MAR 327. (1998) (6)
Pharmacokinetics of fleroxacin as studied by positron emission tomography and [18F]fleroxacin. (1993) (6)
Humoral and cellular immune response in ocular histoplasmosis. (1985) (6)
Temporal aspects of transplant infectious disease (2003) (6)
Poorer outcomes for recipients of heart allografts from HCV-positive donors: opening the silos. (2006) (6)
Monoclonal antibodies to human T cell subsets: use for immunological monitoring and immunosuppression in renal transplantation. (1982) (6)
The prevention and treatment of infectious disease in the transplant patient: where are we now and where do we need to go? (2004) (6)
Changes in immunoregulatory lymphocyte populations in patients with histoplasmosis (1984) (6)
Regional pharmacokinetics of orally administered PET tracers. (2000) (6)
Principles of antimicrobial therapy in the transplant recipient (2004) (6)
Competitive idiotype--anti-idiotype immunoassay for adenosine deaminase binding protein in urine. (1985) (6)
Infection and T lymphocyte subpopulations: changes associated with bacteremia and the acquired immunodeficiency syndrome. (1983) (6)
Prevention of cytomegalovirus infection in the pediatric renal transplant recipient (2004) (6)
The sentinel chicken revisited: the impact of West Nile virus infection on transplant patients. (2004) (6)
Principles of antimicrobial therapy in the transplant patient (2004) (5)
Positron emission tomography in drug development. (1997) (5)
Minimizing the toxicity of antilymphocyte antibody therapy. (1996) (5)
Transplant infectious disease in the twenty-first century (2001) (4)
Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. (1994) (4)
Cytomegalovirus in the transplant population: current issues and future directions. Discussion and consensus points. (1999) (4)
Infections of the Urinary Tract (1998) (4)
The persistent challenges of bacterial infections in the transplant recipient (2006) (4)
The effects of donor pretreatment on the transmission of murine cytomegalovirus with cardiac transplants and explants. (1986) (4)
Polyclonal, nonspecific 111In-IgG scintigraphy in the evaluation of complicated osteomyelitis and septic arthritis. (1999) (4)
Single-Dose Amoxicillin Therapy of Uncomplicated Pediatric Urinary Tract Infections (1983) (4)
Psychiatric disease and cytomegalovirus viremia in renal transplant recipients. (1995) (4)
Infection in the organ transplant patient; the Hegelian dialectic of transplantation. (1994) (3)
The value of randomized clinical trials for daily clinical practice (2007) (3)
Trends, challenges and promotion of clinical and cardiovascular research in Latin America and the Caribbean (2006) (3)
503 5HT2 and D2 receptor occupancy of ziprasidone in healthy volunteers (1997) (3)
Transplant infectious disease: a work in progress (2005) (3)
Reply to Verweij et al (2007) (3)
Case 1-2006: A 64-Year-Old Male Lung-Transplant Recipient with Fever, Cough, Hemoptysis, and Abdominal Pain (2006) (3)
Opportunities and Challenges for Clinical and Cardiovascular Research in Latin America (2006) (3)
The problem of human immunodeficiency virus infection in dialysis and transplantation: the need for an international registry (1988) (3)
Urinary Tract Infection and the Immunocompromised Host: UTI in Renal Transplant Patients (1997) (3)
St. Louis encephalitis in Saline County, Illinois, 1968. (1970) (3)
Non-tumor applications of radioimmune imaging. (1991) (3)
Fungal Infection in the Organ Transplant Recipient: Challenges and Opportunities (1996) (3)
Influenza and the transplant recipient (2002) (3)
P-17-2 Sustained 5HT2A receptor occupancy of ziprasidone using pet ligand 18F setoperone in healthy volunteers (1996) (3)
Fever, Neutropenia, and the Second Law of Thermodynamics (2002) (3)
Expanding the envelope: can we increase the organ donor pool through the appropriate application of infectious disease principles? (2002) (3)
Chapter 37 – Therapy of Urinary Tract Infection (2008) (2)
Pushing the envelope: transplantation and emerging infections (2000) (2)
The role of new diagnostic tests in transplant infectious disease (2002) (2)
The Role of Interferons in Viral Infections in Immune Compromised Patients (1984) (2)
Control of hepatitis in the transplant patient: a journey begun – but not there yet (2000) (2)
Transplant infectious disease as a subspecialty: does outlining how we train define who we are? (2009) (2)
Infection, antimicrobial resistance, and newly emerging pathogens: the growing role of fungi. (2001) (2)
Transplantation and the Second Law of Thermodynamics. (1999) (2)
Antimicrobial prophylaxis in patients undergoing solid organ transplantation. (1995) (2)
Cytomegalovirus and transplantation: yesterday, today, and tomorrow. (1999) (2)
Human Rabies Immune Globulin: Clinical Trials and Effects on Serum Anti-γ-Globulins (1973) (2)
MINIREVIEW Antimicrobial Strategies intheCareofOrgan Transplant Recipients (1993) (2)
PET as a biomarker of the antitumor effects of the CDK2 inhibitor BMS-387032. (2004) (2)
The use of cytomegalovirus cmv immune globulin cmvig for prevention of cmv disease in patients undergoing liver transplantation (1991) (1)
Granulomatous infections in the transplant patient (2003) (1)
Renal transplantation in the highly sensitized recipient. (1987) (1)
Chapter 75 – Infection in solid organ transplantation (2010) (1)
Immunological monitoring of diabetic and nondiabetic recipients of renal allografts. (1983) (1)
Pulmonary infection in solid organ transplant recipients. (1990) (1)
The in vivo and in vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection (2017) (1)
Infections in transplant patients and the role of the microbiology laboratory (1991) (1)
Imaging Techniques in Pharmacology (1991) (1)
Editorial (1999) (1)
Community-Acquired Pneumonia in the Immunocompromised Host (2002) (1)
Use of Monoclonal Antibodies to T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Renal Allografts (1982) (1)
A consideration of potential donors with active infection ‐ is this a way to expand the donor pool? (1998) (1)
INTERFERON IN RENAL TRANSPLANT RECIPIENTS (1982) (1)
Use of T cell subset monitoring in the study of clinical infectious disease problems (1986) (1)
Registry—Acquired Immunodeficiency Syndrome and Clinical Transplantation (1987) (1)
Control of Herpesvirus Infection in Organ Transplant Recipients (1993) (1)
Editorial (1999) (0)
Opportunistic Infect ions in Renal Allograft Recipients (2013) (0)
Preemptive Ganciclovir Therapy in Renal Transplantation (1996) (0)
The Mucocutaneous Problems Associated with Human Immunodeficiency Virus Infection (1994) (0)
Epstein-Barr Virus Infection in Renal Transplant Recipients (2020) (0)
Use of a detectably labeled immunoglobulin or a fragment thereof for producing an agent for the detection of an inflammation site in vivo. (1987) (0)
Antiviral therapy―An anti-malignancy strategy for transplant recipients? (1992) (0)
Editorial (2000) (0)
Case 31-1985: A 43-Year-Old Man with Nine Years of Fever of Unknown Origin (1985) (0)
Letters to the Editor Multidrug-Resistant Trichosporon asahii Isolates Are Susceptible to Voriconazole (2003) (0)
The use of antimicrobial drugs in transplant patients. (2001) (0)
Editorial (2001) (0)
Synthesis of 5-[11C-methyl]-2′-3′-didehydro-3′-deoxythymidine (11C-d4T) (2001) (0)
Case records of the Massachusetts General Hospital. Case 1-2006. A 64-year-old male lung-transplant recipient with fever, cough, hemoptysis, and abdominal pain. (2006) (0)
190: Potential for Racial Disparities in the Proposed Medicare Dialysis Prospective Payment System (2010) (0)
An introduction to organ transplantation. I. (1989) (0)
TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH OKT 3 MONOCLONAL ANTIBODY 1 A (2017) (0)
HST.151 Principles of Pharmacology, Spring 2003 (2003) (0)
Labeled chemotactic peptides for visualization of inflammation and infection sites. (1990) (0)
Infectious Diseases of Transplantation Web Course and e-Conference Room: Building an International Community of Clinicians (2005) (0)
Opportunities and challenges in infectious disease research for the twenty-first century. (1998) (0)
Noninvasive diagnosis of Pneumocystis carinii in the rat using radiolabeled, nonspecific, human polyclonal immunoglobulin. (1989) (0)
P&T Committee review of fluconazole: an effective alternative to antifungal therapy. (1990) (0)
Halo Sign and Improved Outcome. Authors' reply (2007) (0)
A murine model of myocardial microvascular thrombosis this access benefits you. Your story matters (1999) (0)
Cell-Mediated Immunity in Experimental Cytomegalovirus Infections: (1990) (0)
PROPHYLACTIC E5 PROTECTS AGAINST THE HEMODYNAMIC CONSEQUENCES OF ENDOTOXIN (LPS) CHALLENGE IN RABBITS (1993) (0)
Role of radionuclide studies in drug development and evaluation (1992) (0)
Urinary tract infections in women. (1979) (0)
Humoral and cellular immune response in ocular histoplasmosis. (1985) (0)
THE INFLUENCE OF HUMAN ANTI-MOUSE ANTIBODY (HAMA) INDUCED BY OKT3 ON THE PROTECTIVE EFFECTS OF E5 IN A SHEEP MODEL OF ARDS (1993) (0)
sensitivity in HIV-lipodystrophy Depot-specific regulation of glucose uptake and insulin (2016) (0)
Infection in Patients Undergoing Thoracic Organ Transplantation: Epidemiology, Pathogenesis, and Clinical Management (1996) (0)
Introduction to the Symposium (1990) (0)
Editorial (1999) (0)
Darwinian competition and the pathogenesis of opportunistic infection in the transplant recipient * (2005) (0)
Measurement of tissue pharmacokinetics of antimicrobial agents by positron emission tomography (1999) (0)
Editorial (2001) (0)
Editorial (2001) (0)
Editorial (2001) (0)
The acquired immunodeficiency syndrome (AIDS) and infection with the human immunodificiency virus (HIV) (1990) (0)
The labeled chemotactic peptides of infection or inflammation of the entries describe the (1996) (0)
Diagnosis of opportunistic infections in the transplant patient (2003) (0)
Prevents DeathbutNot Immunity inMurineCytomegalovirus-Infected Normaland (1987) (0)
Individualization in the management of fungal disease in the transplant recipient (2007) (0)
Cytomegalovirus in the transplant population: current issues and future directions. An introduction to the symposium. (1999) (0)
Editor's introduction to guest editorial (2004) (0)
Radionuclide imaging of infection in soft tissue and bone. (1997) (0)
Vol. 8, No. 1, 2006 (2006) (0)
Effect of isotype on the biodistribution of radioiodinated immunoglobulins (1985) (0)
Art and science in the clinical management of the patient with infection and/or cancer (2004) (0)
persons with AIDS. correlations in transplant recipients and in Cytomegalovirus antigenemia: clinical (2013) (0)
The Acquired lmmunodeficiency Syndrome ( AIDS ) and Infection with Human lmmunodeficiency Virus ( HIV ) (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert H. Brookline Rubin?

Robert H. Brookline Rubin is affiliated with the following schools: